Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer

NCT03596281 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Bevacizumab
DRUG: pegylated liposomal doxorubicin (PLD)

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris